Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Certain non-cardiac drugs increase the risk of sudden death

The use of non-cardiac QTc-prolonging drugs, such as cisapride and domperidone used to treat gastro-intestinal conditions, is associated with an increased risk of sudden cardiac death, finds the latest publication in European Heart Journal.

News image

fiogf49gjkf04

QTc is a measurement of the electrical activity linked to the contraction of heart muscle cells.

Drugs that increase the QTc interval can cause life-threatening disruptions of heart rhythms.

Dr Stricker and colleagues from the Netherlands assessed the association between the use of non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.

The researchers performed a population-based case-control study in the Integrated Primary Care Information project, a longitudinal observational database.

The team reviewed the complete medical records from more than 500 000 persons and all deaths between 1995 and 2003.

The 7 drugs studied are likely to be responsible for 320 of the 775 sudden deaths
European Heart Journal

Sudden cardiac death was classified based on the time between onset of cardiovascular symptoms and death.

For each case, the researchers matched up to 10 random controls for age, gender, date of sudden death and general practice.

The exposure of interest was the use of non-cardiac QTc-prolonging drugs.

Of the 7 drugs studied, 2 included the antibiotics erythromycin and clarithromycin.

Others on the risk-list are cisapride and domperidone, which are used to treat gastro-intestinal conditions, and the anti-psychotic medications chlorpromazine, haloperidol and pimozide.

The researchers categorized the exposure at the index date into 3 mutually exclusive groups of current use, past use, and non-use.

The team reported that the study population comprised 775 cases of sudden cardiac death and 6297 matched controls.

The research team found that current use of any non-cardiac QTc-prolonging drug was associated with a significantly increased risk of sudden cardiac death.

The 7 drugs studied were likely to have been responsible for 320 of these deaths, equating to about 1200 deaths in the UK and 15,000 across Europe and the US.

The drugs were found to interfere with the electrical activity controlling the heartbeat, increasing the risk of sudden death due to cardiac arrest by 3 times.

The team observed that the risk of death was highest in women, older patients and in recent starters of less than 90 days.

Dr Stricker concludes, “The use of non-cardiac QTc-prolonging drugs in a general population is associated with an increased risk of sudden cardiac death.”

"These drugs are vital treatments for serious conditions in many cases, so it is essential that patients should not stop taking them on their own initiative, but talk to their doctors.”

Eur Heart J: 11 May 2005, advanced online, doi:10.1093/eurheartj/ehi312
12 May 2005

Go to top of page Email this page Email this page to a colleague

 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us